在阿尔茨海默氏症患者中,电-解之前的神经退行
bioRxiv : the preprint server for biology
|February 9, 2026
概括
早期的阿尔茨海默氏症涉及由于毛细血管内皮细胞中电- (E-Ca) 合中断的血液流动受损. 在5xFAD小鼠中,这种神经血管缺陷在认知衰退之前,突出了潜在的治疗目标.
科学领域:
- 神经科学是一个神经科学.
- 血管生物学 血管生物学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 越来越多的人认识到阿尔茨海默病 (AD) 有血管成分.
- 在AD患者临床症状出现之前,脑输液减少发生,但早期神经血管缺陷机制尚不清楚.
- 功能性高血症对大脑健康至关重要,它依赖于毛细血管内皮细胞 (cEC) 中的电和信号的结合.
研究的目的:
- 研究阿尔茨海默病早期神经血管功能障碍的机制.
- 在小鼠模型中确定电- (E-Ca) 合缺陷是否先于神经退行和认知衰退.
- 为了确定特定的离子通道功能障碍,导致早期AD的功能性高血症受损.
主要方法:
- 使用了3个月大的5xFAD小鼠,这是家族性阿尔茨海默病模型.
- 通过体内成像测量胡须刺激诱导的功能性高血压和皮质神经/内皮质 (Ca2+) 活性.
- 评估了毛细体内皮细胞 (cEC) 离子通道功能 (KIR2.1,TRPV4) 和电流密度.
主要成果:
- 5xFAD小鼠显示功能性高血症减少,没有认知或神经元缺陷.
- 在5xFAD小鼠中,毛囊内皮细胞的Ca2+活性显著降低.
- 损伤的TRPV4通道功能,而不是KIR2.1,被确定为E-Ca脱和高血压缺陷的原因.
结论:
- 在CEC中早期的E-Ca脱导致阿尔茨海默氏病模型中的功能性高血症受损.
- 血管缺陷,特别是TRPV4通道功能障碍,在阿尔茨海默氏症中先于神经退行和认知衰退.
- 准E-Ca合是对阿尔茨海默病早期干预的潜在策略.
相关概念视频
Neural Regulation
45.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
45.0K
Long-term Depression
3.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.6K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.9K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.9K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K


